Finally, Citigroup raised their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback